BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15089767)

  • 1. Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide.
    Ishitsuka K; Shirahashi A; Iwao Y; Shishime M; Takamatsu Y; Takatsuka Y; Utsunomiya A; Suzumiya J; Hara S; Tamura K
    Eur J Haematol; 2004 Apr; 72(4):280-4. PubMed ID: 15089767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
    Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
    Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
    [No Abstract]   [Full Text] [Related]  

  • 3. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.
    Galimberti S; Papineschi F; Carmignani A; Testi R; Fazzi R; Petrini M
    Bone Marrow Transplant; 1999 Aug; 24(3):345-8. PubMed ID: 10455379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Ni J; Chen G; Shen Z; Li X; Liu H; Huang Y; Fang Z; Chen S; Wang Z; Chen Z
    Chin Med J (Engl); 1998 Dec; 111(12):1107-10. PubMed ID: 11263375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated arsenic trioxide intravenous infusion causes focal bone marrow necrosis in two acute promyelocytic leukemia patients.
    Zhou J; Meng R; Sui XH; Yang BF
    Chin Med Sci J; 2004 Dec; 19(4):281. PubMed ID: 15669187
    [No Abstract]   [Full Text] [Related]  

  • 6. Hyperleukocytosis from arsenic trioxide.
    Levy M; Wofford MM; Powell BL; McLean TW
    Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
    Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
    Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide associated toothache.
    Siderov J; Duggan J
    J Oncol Pharm Pract; 2010 Jun; 16(2):127-8. PubMed ID: 19525303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
    Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
    Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease.
    Visani G; Piccaluga PP; Martinelli G; Rossi M; Malagola M; Baccarani M
    Haematologica; 2003 Apr; 88(4):ELT15. PubMed ID: 12681992
    [No Abstract]   [Full Text] [Related]  

  • 11. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
    Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
    Fujisawa S; Ohno R; Shigeno K; Sahara N; Nakamura S; Naito K; Kobayashi M; Shinjo K; Takeshita A; Suzuki Y; Hashimoto H; Kinoshita K; Shimoya M; Kaise T; Ohnishi K
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):485-93. PubMed ID: 16937107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
    Krishna R; Sorour Y; Goepel JR; Kirkbride P; Smith DJ; Ezaydi Y; Dalley CD; Snowden JA
    Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):769-71. PubMed ID: 18995171
    [No Abstract]   [Full Text] [Related]  

  • 14. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
    Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
    Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
    Sasaki M; Sugimoto K; Isobe Y; Oshimi K
    Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
    [No Abstract]   [Full Text] [Related]  

  • 17. Fluid retention during arsenic trioxide treatment in acute promyelocytic leukemia.
    Arai A; Kitano A; Kurosu T; Yamamoto K; Miki T; Murakami N; Miura O
    Am J Hematol; 2005 Jul; 79(3):247-8. PubMed ID: 15981228
    [No Abstract]   [Full Text] [Related]  

  • 18. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
    Ma J
    Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute promyelocytic leukemia complicated by massive intracerebral hemorrhage: safety and efficacy of replacing conventional chemotherapy with arsenic trioxide in an adolescent.
    Müller E; Seidel MG; Lackner H; Dworzak M; Urban C
    Klin Padiatr; 2013 May; 225(3):172-3. PubMed ID: 23625686
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Park JA; Yun JH; Kang HJ; Shin HY; Ahn HS
    Pediatr Blood Cancer; 2008 Apr; 50(4):872-4. PubMed ID: 17635008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.